- Title: Subtitle
- Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Creators
- Rashmi Khanal - Fox Chase Cancer CenterJennifer N. Saultz - University of PortlandUmar Farooq - University of IowaSunita Nathan - Rush University Medical CenterAmitkumar Mehta - University of Alabama at BirminghamAyad Hamdan - University of California San DiegoLawrence E. Morris - Northside HospitalHouston Holmes - Texas OncologyLauren C. Pinter-Brown - Orange (Belgium)John K.C. Lim - Multimeric Biotherapeutics (United States)Amanda Conerty - Multimeric Biotherapeutics (United States)Heather Raymon - Multimeric Biotherapeutics (United States)Peter Flynn - Multimeric Biotherapeutics (United States)Anita G. Seto - Multimeric Biotherapeutics (United States)Joseph J. Maly - 11Norton Cancer Institute, Louisville, KY
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.12742-12743
- DOI
- 10.1182/blood-2022-159282
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362349302771
Abstract
Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Blood, Vol.140(Supplement 1), pp.12742-12743
11/15/2022
DOI: 10.1182/blood-2022-159282
Details
Metrics
14 Record Views